Antiviral and anti-inflammatory therapies in COVID-19

被引：11

作者：

Szekanecz Zoltan ^{[1
]}

Bogos Krisztina ^{[2
]}

Constantin Tamas ^{[3
]}

Fullesdi Bela ^{[4
]}

Muller Veronika ^{[5
]}

Rakoczi Eva ^{[1
]}

Varkonyi Istvan ^{[6
]}

Valyi-Nagy Istvan ^{[7
]}

机构：

[1] Debreceni Egyet, Altalanos Orvostud Kar, Belgyogyaszati Klin, Reumatol, Debrecen, Hungary

[2] Orszagos Koranyi Pulmonol Int, Budapest, Hungary

[3] Semmelweis Egyet, Altalanos Orvostud Kar, Gyermekgyogyaszati Klin 2, Budapest, Hungary

[4] Debreceni Egyet, Altalanos Orvostud Kar, Aneszteziol & Intenz Terapias Klin, Debrecen, Hungary

[5] Semmelweis Egyet, Altalanos Orvostud Kar, Pulmonol Klin, Budapest, Hungary

[6] Debreceni Egyet, Altalanos Orvostud Kar, Infektol Klin, Debrecen, Hungary

[7] Del Pesti Ctr Korhaz, Orszagos Hematol & Infektol Int, Budapest, Hungary

来源：

ORVOSI HETILAP | 2021年 / 162卷 / 17期

关键词：

novel coronavirus infection (COVID-19); coronavirus; cytokine storm; antiviral treatment; cytokine in-hibition treatment; corticosteroid; interleukin-6; inhibition; Janus kinase inhibition; intravenous immunoglobulin; TOCILIZUMAB; MULTICENTER;

D O I：

10.1556/650.2021.32230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The novel coronavirus infection (COVID-19) places a heavy burden on the health care system and our society. There are three major stages in the disease that fundamentally determine treatment approaches. Phases I?IIA require primarily antiviral treatment. In phases IIB?III, anti-inflammatory treatment is needed accompanied by intensive and supportive care. This recommendation applies only to pharmacotherapy and summarizes the therapeutic options based on the available evidence. It also includes a proposed treatment algorithm.

引用

页码：643 / 651

页数：9

共 50 条

[21] The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties
Lippi, Giuseppe
Henry, Brandon M.
Favaloro, Emmanuel J.
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (01): : 73 - 75
[22] Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Yamaya, Takafumi
Hagiwara, Eri
Baba, Tomohisa
Iwasawa, Tae
Ogura, Takashi
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (07) : 1029 - 1032
[23] Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection
Shrivastava, Ravi
Shrivastava, Remi
Johansen, Bianca
Allain, Thibault
JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 1195 - 1206
[24] The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Yamaya, Takafumi
Hagiwara, Eri
Baba, Tomohisa
Iwasawa, Tae
Ogura, Takashi
EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[25] COVID-19, POST-COVID. ANTI-INFLAMMATORY THERAPEUTIC INTERVENTIONS
Athanassiou, P.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S91 - S91
[26] Non-steroidal anti-inflammatory drugs and covid-19
Little, Paul
BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
[27] Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia
Santus, Pierachille
Radovanovic, Dejan
Garziano, Micaela
Pini, Stefano
Croce, Giuseppe
Fuccia, Giuseppe
Spitaleri, Debora
Biasin, Mara
Clerici, Mario
Trabattoni, Daria
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (24)
[28] Finding the right time for anti-inflammatory therapy in COVID-19
de Simone, Giovanni
Mancusi, Costantino
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 247 - 248
[29] Use of Psychotropics in COVID-19: Another Anti-inflammatory Pathway
Morillo, Jessenia
Morillo, Valery
Marquina, Maria Angelica
Rojas, Milagros
Nava, Manuel
CURRENT PSYCHIATRY RESEARCH AND REVIEWS, 2023, 19 (02) : 137 - 146
[30] Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19
Sestili, Piero
Stocchi, Vilberto
FRONTIERS IN PHARMACOLOGY, 2020, 11

← 1 2 3 4 5 →